Dr. Kevin Suk is a native of Southern California and grew up in the city of Downey. He received his bachelor of science in biology at the University of California, Los Angeles. While at UCLA, he was nominated to the Phi Beta Kappa and Phi Sigma academic honor societies and graduated summa cum laude with highest departmental honors in biology. He then earned his medical degree at Loma Linda University School of Medicine on a merit scholarship and was elected to the Alpha Omega Alpha Honor Medical Society.
Dr. Suk then completed his ophthalmology residency at Henry Ford Hospital in Detroit, Michigan after which he furthered his training by completing a two-year vitreoretinal fellowship at the renowned Bascom Palmer Eye Institute in Miami, Florida. The Bascom Palmer Eye Institute is consistently ranked as the nation’s best ophthalmic hospital by the US News and World Report survey of board-certified ophthalmologists from across the country. While there, he trained under Dr. Harry Flynn, Jr., MD, and Dr. William Smiddy, MD, pioneers and authorities in the treatment of diabetic retinopathy and macular hole, as well as Dr. Philip Rosenfeld, MD, PhD, who first began the use of bevacizumab (Avastin) in the treatment of age related macular degeneration.
Dr. Suk has presented at several national meetings, including the Annual American Association for Pediatric Ophthalmology and Strabismus (AAPOS) meeting and the Association of Research in Vision and Ophthalmology annual meeting, and has published his work in peer-reviewed journals. His special interests are in the treatment of the vitreoretinal complications of diabetic retinopathy, macular hole repair and retinal detachment surgery. He is a member of the American Academy of Ophthalmology, American Society of Retina Specialists and the American Medical Association.